E J Sorenson

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Motor unit number estimates correlate with strength in polio survivors
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Muscle Nerve 34:608-13. 2006
  2. doi request reprint The electrophysiology of the motor neuron diseases
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Neurol Clin 30:605-20. 2012
  3. ncbi request reprint Effect of referral bias on assessing survival in ALS
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 68:600-2. 2007
  4. ncbi request reprint Electrophysiological findings in a cohort of old polio survivors
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Peripher Nerv Syst 11:241-6. 2006
  5. ncbi request reprint Incidence of adaptive equipment use in subjects with a remote history of paralytic poliomyelitis
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 65:963. 2005
  6. ncbi request reprint Elevated creatine kinase and transaminases in asymptomatic SBMA
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Amyotroph Lateral Scler 8:62-4. 2007
  7. ncbi request reprint Incidence of aspiration pneumonia in ALS in Olmsted County, MN
    Eric J Sorenson
    Department of Neurology, Mayo Clinic Rochester, MN 55905, USA
    Amyotroph Lateral Scler 8:87-9. 2007
  8. doi request reprint Neurological injuries associated with regional anesthesia
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Reg Anesth Pain Med 33:442-8. 2008
  9. pmc Subcutaneous IGF-1 is not beneficial in 2-year ALS trial
    E J Sorenson
    Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neurology 71:1770-5. 2008
  10. ncbi request reprint Obturator neuropathy: causes and outcome
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Muscle Nerve 25:605-7. 2002

Research Grants

  1. QUANTITATIVE FUNCTION IN MOTOR NEURON DISEASE
    Eric Sorenson; Fiscal Year: 2004
  2. IGF-I/ALS Trial
    Eric Sorenson; Fiscal Year: 2006
  3. IGF-I/ALS Trial
    Eric Sorenson; Fiscal Year: 2007

Detail Information

Publications28

  1. ncbi request reprint Motor unit number estimates correlate with strength in polio survivors
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Muscle Nerve 34:608-13. 2006
    ..These findings confirm the clinical relevance of MUNE as an outcome measure in the motor neuron diseases and provide further validation for its use in clinical trial research...
  2. doi request reprint The electrophysiology of the motor neuron diseases
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Neurol Clin 30:605-20. 2012
    ..Newer neurophysiology techniques have been developed in the past several years. What role these techniques will play in clinical practice is currently unknown...
  3. ncbi request reprint Effect of referral bias on assessing survival in ALS
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neurology 68:600-2. 2007
    ..007). Referral bias should be addressed when assessing the efficacy of self-selected therapies in the setting of a tertiary ALS clinic...
  4. ncbi request reprint Electrophysiological findings in a cohort of old polio survivors
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Peripher Nerv Syst 11:241-6. 2006
    ..Of these two models of neuron loss, the proportional loss of motor neurons was a better fit of the data than a linear loss...
  5. ncbi request reprint Incidence of adaptive equipment use in subjects with a remote history of paralytic poliomyelitis
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 65:963. 2005
  6. ncbi request reprint Elevated creatine kinase and transaminases in asymptomatic SBMA
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Amyotroph Lateral Scler 8:62-4. 2007
    ..These cases emphasize the need to consider SBMA and genetic testing for the androgen receptor trinucleotide CAG expansion in males otherwise healthy with 'idiopathic' elevated creatinine kinase...
  7. ncbi request reprint Incidence of aspiration pneumonia in ALS in Olmsted County, MN
    Eric J Sorenson
    Department of Neurology, Mayo Clinic Rochester, MN 55905, USA
    Amyotroph Lateral Scler 8:87-9. 2007
    ..Aspiration pneumonia occurs in a minority but is associated with a high mortality. ALS subjects residing in nursing homes are at the greatest risk...
  8. doi request reprint Neurological injuries associated with regional anesthesia
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Reg Anesth Pain Med 33:442-8. 2008
    ..The prognosis for cauda equina or spinal cord lesions is more guarded. Recovery from these is commonly incomplete. Early diagnosis and intervention is the key to preventing catastrophic neurological outcomes...
  9. pmc Subcutaneous IGF-1 is not beneficial in 2-year ALS trial
    E J Sorenson
    Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neurology 71:1770-5. 2008
    ..This phase III, randomized, double-blind, placebo-controlled study was undertaken to address whether IGF-1 benefited patients with ALS...
  10. ncbi request reprint Obturator neuropathy: causes and outcome
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Muscle Nerve 25:605-7. 2002
    ..Twenty-two patients with obturator neuropathy were identified. The clinical outcome of patients with acute obturator neuropathy treated conservatively was good regardless of etiology or severity...
  11. ncbi request reprint Emerging strategies for drug development in motor neuron disease
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Expert Opin Investig Drugs 11:483-9. 2002
    ..A hierarchical approach such as this will be even more important as multi-drug regimens are to be studied. The number of combinations for these multi-drug regimens becomes prohibitive without a screening method...
  12. ncbi request reprint An acute, life-threatening, hypersensitivity reaction to riluzole
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Neurology 67:2260-1. 2006
  13. ncbi request reprint Suramin-induced neuropathy in an animal model
    J W Russell
    University of Michigan, Department of Neurology, 4414 Kresge III, 200 Zina Pitcher Place, Ann Arbor, MI 48109 0588, USA
    J Neurol Sci 192:71-80. 2001
    ..Suramin induced a length, dose and time-dependent axonal sensorimotor polyneuropathy associated with axonal degeneration, atrophy, and accumulation of glycolipid lysosomal inclusions...
  14. doi request reprint Clinical and imaging characterization of progressive spastic dysarthria
    H M Clark
    Division of Speech Pathology, Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Eur J Neurol 21:368-76. 2014
    ..To describe speech, neurological and imaging characteristics of a series of patients presenting with progressive spastic dysarthria as the first and predominant sign of a presumed neurodegenerative disease...
  15. ncbi request reprint Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
    R G Miller
    Department of Neurology, California Pacific Medical Center, San Francisco, USA
    Neurology 56:843-8. 2001
    ..Preclinical and clinical studies of gabapentin in patients with ALS led the authors to undertake a phase III randomized clinical trial...
  16. doi request reprint A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
    Paul H Gordon
    Department of Neurology, Columbia University, New York, USA
    Amyotroph Lateral Scler 9:212-22. 2008
    ..This phase II design was efficient, leading to treatment selection after just 60 patients, and can be used in other phase II trials to assess different agents...
  17. pmc Misdirection of regenerating motor axons after nerve injury and repair in the rat sciatic nerve model
    Godard C W de Ruiter
    Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, USA
    Exp Neurol 211:339-50. 2008
    ..The results of this study can be used as basis for developing new nerve repair techniques that may improve the accuracy of regeneration...
  18. ncbi request reprint Regional anesthesia does not increase the risk of postoperative neuropathy in patients undergoing ulnar nerve transposition
    J R Hebl
    Department of Anesthesiology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Anesth Analg 93:1606-11, table of contents. 2001
    ..We conclude that axillary blockade is a suitable anesthetic technique for this procedure...
  19. pmc Predicting survival in frontotemporal dementia with motor neuron disease
    E A Coon
    Department of Behavioral Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 76:1886-93. 2011
    ..To determine whether clinical and demographic features are associated with prognosis in patients with frontotemporal dementia and motor neuron disease (FTD-MND)...
  20. ncbi request reprint Comparison of clinical methods for fasciculation detection in amyotrophic lateral sclerosis
    Farrah J Mateen
    Muscle Nerve 36:404-5. 2007
  21. ncbi request reprint Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 59:280-2. 2002
    ..02). Mean time from symptom onset to diagnosis was 13 months. Neither survival nor time to diagnosis changed significantly over time...
  22. ncbi request reprint Role of insulin-like growth factor-I in the treatment of painful small fiber predominant neuropathy
    Anthony J Windebank
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Peripher Nerv Syst 9:183-9. 2004
    ..Analysis of secondary endpoints and a global impression of improvement by patients and physicians did not show consistent differences between the groups. IGF-I was safe, but did not improve symptoms in this 6-month trial...
  23. ncbi request reprint A 15-year follow-up of neuromuscular function in patients with prior poliomyelitis
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 64:1070-2. 2005
    ..There was no association between symptoms of late deterioration and magnitude of decline. Rather, the presence of these symptoms was associated with the magnitude of the residual deficits...
  24. ncbi request reprint Neurologic course, endocrine dysfunction and triplet repeat size in spinal bulbar muscular atrophy
    Michael Sinnreich
    Peripheral Neuropathy Research Laboratory, Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Can J Neurol Sci 31:378-82. 2004
    ..To study the role of diabetes, gynecomastia and CAG triplet repeat size as disease modifying factors of neurologic expression in spinal bulbar muscular atrophy (SBMA, Kennedy's disease)...
  25. doi request reprint Strength, physical activity, and fasciculations in patients with ALS
    Farrah J Mateen
    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
    Amyotroph Lateral Scler 9:120-1. 2008
    ..05) and limb atrophy (p>0.05). No prediction of disease duration could be made based on fasciculation frequency alone. Fasciculations therefore appear to have diagnostic, but not prognostic, utility in the care of people with ALS...
  26. pmc Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway
    Timothy G Lesnick
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 3:e1449. 2008
    ..We also demonstrated that several axon guidance pathway genes represented by SNPs within our final models were differentially expressed in PD...
  27. ncbi request reprint What is next in ALS clinical trials?
    Eric J Sorenson
    Neurology 69:719-20. 2007
  28. ncbi request reprint Monozygotic twins discordant for primary lateral sclerosis
    Eric J Sorenson
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Amyotroph Lateral Scler 7:123-5. 2006
    ..Their life history suggests very similar social and professional exposures without any apparent distinctions...

Research Grants9

  1. QUANTITATIVE FUNCTION IN MOTOR NEURON DISEASE
    Eric Sorenson; Fiscal Year: 2004
    ..This will become increasingly important as our population ages, increasing demands for medical and social resources. ..
  2. IGF-I/ALS Trial
    Eric Sorenson; Fiscal Year: 2006
    ..The preliminary data from our prior trial allows design of a Phase III treatment trial that will yield a definitive result about the treatment effect of IGF-1. ..
  3. IGF-I/ALS Trial
    Eric Sorenson; Fiscal Year: 2007
    ..The preliminary data from our prior trial allows design of a phase III treatment trial that will yield a definitive result about the treatment effect of IGF-I. ..